The Experts below are selected from a list of 126 Experts worldwide ranked by ideXlab platform
Finn Edler Von Eyben - One of the best experts on this subject based on the ideXlab platform.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular and Ovarian Germ Cell Tumours
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, Mansoor Raza Mirza, B. HølundAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) is raised both in patients with ovarian germ cell tumours (OGCT) and with testicular germ cell tumours (TGCT). This overview combines results from the literature with the experience at a single oncological institution.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular Seminoma or Nonseminoma Stage I: Two Nationwide Danish Studies of Surveillance
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, G K Jacobsen, Lena Specht, Ebbe Lindegard Madsen, Mikael Rørth, H. Von Der MaaseAbstract:The use of surveillance in patients with stage I testicular germ cell tumours is increasing internationally. The aim of this study was to elucidate pathological and clinical aspects of serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration in this setting.
-
serum Lactate Dehydrogenase Isoenzyme 1 in patients with seminoma stage i followed with surveillance
Acta Oncologica, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, Lena Specht, Bent Pedersen, H. Von Der MaaseAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured in patients with testicular seminoma clinical stage I followed with surveillance after orchiectomy. The serum samples were obtained before orchiectomy in 110 patients (group A) and soon after orchiectomy in 55 patients (group B). In group A, 60 patients (55%) had elevated S-LD-1 and 10 patients (9%) had elevated serum human chorionic gonadotropin concentrations (S-hCG). In group B, median S-LD-1 was lower than that of group A and decreased with increasing time after orchiectomy (pae0.001, Jonckheere-Terpstra test, one-sided). After a median follow-up of 5.1 years, 23 patients (21%) in group A had relapses. The patients with elevated S-LD-1 and those with normal S-LD-1 had a similar relapse-free survival (pae0.79, log-rank test). Thus patients with seminoma stage I had elevated S-LD-1 more often than elevated S-hCG but an elevation in S-LD-1 did not predict a relapse during follow-up with surveillance. Further studies are required to elucidate the value of S-LD-1 in monitoring the surveillance of patients with seminoma stage I.
-
a systematic review of Lactate Dehydrogenase Isoenzyme 1 and germ cell tumors
Clinical Biochemistry, 2001Co-Authors: Finn Edler Von EybenAbstract:Objectives: To evaluate Lactate Dehydrogenase Isoenzyme 1 (LD-1) as a tumor marker of germ cell tumors. Methods: A literature search included a CancerLit and Medline computer search of articles regarding germ cell tumors and LD-1 published between 1963 to 99 and a manual search of reference lists, theses, and textbooks. Forty articles, letters to the editor, and abstracts on testicular germ cell tumors and 10 articles on ovarian germ cell tumors fulfilled inclusion criteria. Results: Of 696 patients with testicular germ cell tumors, 423 (61%) had a raised serum LD-1 catalytic concentration (S-LD-1). Patients with seminoma have a raised S-LD-1 more often (63%) than those with nonseminoma (60%). S-LD-1 was raised less often in patients with stage I (48%) than in those with stage II (50%) and stage III (67%). S-LD-1, serum alpha fetoprotein concentration (S-AFP), and serum human chorionic gonadotropin concentration (S-hCG) were discordant. S-LD-1 predicted outcome in four studies: one study regarding relapse in patients with nonseminomatous testicular germ cell tumors stage I, and three studies regarding survival of patients with metastatic testicular germ cell tumors. In two of three studies, S-LD-1 was a better prognostic predictor for patients with metastatic testicular germ cell tumors than S-LD. Of 40 patients with ovarian germ cell tumors, thirty-five (88%) had a raised S-LD-1. Conclusions: S-LD-1 is a useful serum tumor marker of testicular germ cell tumors. For patients with ovarian germ cell tumors, S-LD-1 was raised more often than for patients with testicular germ cell tumors. Further studies are required for a general recommendation regarding the use of S-LD-1 for germ cell tumors. © 2001 The Canadian Society of Clinical Chemists. All rights reserved.
-
serum Lactate Dehydrogenase Isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage i
Acta Oncologica, 2001Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, H. Von Der Maase, Mikael RørthAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured at the time of orchiectomy in 104 patients with nonseminomatous testicular germ cell tumors (NSTGCT) clinical stage I who participated in a randomized study comparing surveillance after orchiectomy (group I) and radiotherapy (group II). For 68 patients, S-LD-1 was measured in a serum sample before or on the day of the orchiectomy. Twenty-seven patients (40%) had elevated S-LD-1; median 102 U/L (range 41-335). For the remaining 36 patients, S-LD-1 was measured in a serum sample after orchiectomy: 8 of these patients (22%) had elevated S-LD-1. S-LD-1 was normalized shortly after surgery in most patients with a preorchiectomy elevated S-LD-1. Fifteen of the 68 patients relapsed: 9 out of 27 with an elevated S-LD-1 and 6 out of 41 patients with normal S-LD-1 (p = 0.13, Fisher's exact test). In group I, those with a preoperatively elevated S-LD-1 had a lower 8-years' relapse-free survival than those with a normal S-LD-1 (40% ...
Ole Blaabjerg - One of the best experts on this subject based on the ideXlab platform.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular and Ovarian Germ Cell Tumours
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, Mansoor Raza Mirza, B. HølundAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) is raised both in patients with ovarian germ cell tumours (OGCT) and with testicular germ cell tumours (TGCT). This overview combines results from the literature with the experience at a single oncological institution.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular Seminoma or Nonseminoma Stage I: Two Nationwide Danish Studies of Surveillance
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, G K Jacobsen, Lena Specht, Ebbe Lindegard Madsen, Mikael Rørth, H. Von Der MaaseAbstract:The use of surveillance in patients with stage I testicular germ cell tumours is increasing internationally. The aim of this study was to elucidate pathological and clinical aspects of serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration in this setting.
-
serum Lactate Dehydrogenase Isoenzyme 1 in patients with seminoma stage i followed with surveillance
Acta Oncologica, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, Lena Specht, Bent Pedersen, H. Von Der MaaseAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured in patients with testicular seminoma clinical stage I followed with surveillance after orchiectomy. The serum samples were obtained before orchiectomy in 110 patients (group A) and soon after orchiectomy in 55 patients (group B). In group A, 60 patients (55%) had elevated S-LD-1 and 10 patients (9%) had elevated serum human chorionic gonadotropin concentrations (S-hCG). In group B, median S-LD-1 was lower than that of group A and decreased with increasing time after orchiectomy (pae0.001, Jonckheere-Terpstra test, one-sided). After a median follow-up of 5.1 years, 23 patients (21%) in group A had relapses. The patients with elevated S-LD-1 and those with normal S-LD-1 had a similar relapse-free survival (pae0.79, log-rank test). Thus patients with seminoma stage I had elevated S-LD-1 more often than elevated S-hCG but an elevation in S-LD-1 did not predict a relapse during follow-up with surveillance. Further studies are required to elucidate the value of S-LD-1 in monitoring the surveillance of patients with seminoma stage I.
-
serum Lactate Dehydrogenase Isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage i
Acta Oncologica, 2001Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, H. Von Der Maase, Mikael RørthAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured at the time of orchiectomy in 104 patients with nonseminomatous testicular germ cell tumors (NSTGCT) clinical stage I who participated in a randomized study comparing surveillance after orchiectomy (group I) and radiotherapy (group II). For 68 patients, S-LD-1 was measured in a serum sample before or on the day of the orchiectomy. Twenty-seven patients (40%) had elevated S-LD-1; median 102 U/L (range 41-335). For the remaining 36 patients, S-LD-1 was measured in a serum sample after orchiectomy: 8 of these patients (22%) had elevated S-LD-1. S-LD-1 was normalized shortly after surgery in most patients with a preorchiectomy elevated S-LD-1. Fifteen of the 68 patients relapsed: 9 out of 27 with an elevated S-LD-1 and 6 out of 41 patients with normal S-LD-1 (p = 0.13, Fisher's exact test). In group I, those with a preoperatively elevated S-LD-1 had a lower 8-years' relapse-free survival than those with a normal S-LD-1 (40% ...
-
analytical quality specifications for serum Lactate Dehydrogenase Isoenzyme 1 based on clinical goals
Clinical Chemistry and Laboratory Medicine, 1999Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard MadsenAbstract:The aim of the study was to deduce analytical quality specifications for the determination of catalytic concentration of serum Lactate Dehydrogenase Isoenzyme 1 (S-LD-1) according to clinical goals (the clinical utility model). We defined clinical goals for false positive and false negative S-LD-1 measurements in the monitoring of patients with testicular germ cell tumors (TGCT), clinical stage I, on a surveillance only program. The absolute S-LD-1 catalytic concentrations were routinely corrected for contamination from preanalytical hemolysis. A reference group of 37 men had a near In-Gaussian distribution for the absolute S-LD-1 catalytic concentration. The geometric mean was 76 U/l and an S-LD-1 >128 U/l (99.72 percentile, the decision limit) indicated a high risk of a relapse of TGCT. We have previously shown that an S-LD-1 >160 U/l (treatment limit) was associated with a suboptimal outcome from the treatment of metastatic TGCT. The maximum allowable analytical positive bias was 5 U/l, and the maximum allowable analytical negative bias was -32 U/l. The maximum allowable analytical coefficient of variation, CV(A), was 11% (approximately 14 U/l) at a bias = -5 U/l. For S-LD-1 measurements not corrected for hemolysis, the decision limit was 145 U/l, the maximum allowable negative bias -19 U/l, and CV(A) 8%(approximately 12 U/l). A routine correction for hemolysis had a large impact on the analytical quality specifications.
Ebbe Lindegaard Madsen - One of the best experts on this subject based on the ideXlab platform.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular and Ovarian Germ Cell Tumours
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, Mansoor Raza Mirza, B. HølundAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) is raised both in patients with ovarian germ cell tumours (OGCT) and with testicular germ cell tumours (TGCT). This overview combines results from the literature with the experience at a single oncological institution.
-
serum Lactate Dehydrogenase Isoenzyme 1 in patients with seminoma stage i followed with surveillance
Acta Oncologica, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, Lena Specht, Bent Pedersen, H. Von Der MaaseAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured in patients with testicular seminoma clinical stage I followed with surveillance after orchiectomy. The serum samples were obtained before orchiectomy in 110 patients (group A) and soon after orchiectomy in 55 patients (group B). In group A, 60 patients (55%) had elevated S-LD-1 and 10 patients (9%) had elevated serum human chorionic gonadotropin concentrations (S-hCG). In group B, median S-LD-1 was lower than that of group A and decreased with increasing time after orchiectomy (pae0.001, Jonckheere-Terpstra test, one-sided). After a median follow-up of 5.1 years, 23 patients (21%) in group A had relapses. The patients with elevated S-LD-1 and those with normal S-LD-1 had a similar relapse-free survival (pae0.79, log-rank test). Thus patients with seminoma stage I had elevated S-LD-1 more often than elevated S-hCG but an elevation in S-LD-1 did not predict a relapse during follow-up with surveillance. Further studies are required to elucidate the value of S-LD-1 in monitoring the surveillance of patients with seminoma stage I.
-
serum Lactate Dehydrogenase Isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage i
Acta Oncologica, 2001Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, H. Von Der Maase, Mikael RørthAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured at the time of orchiectomy in 104 patients with nonseminomatous testicular germ cell tumors (NSTGCT) clinical stage I who participated in a randomized study comparing surveillance after orchiectomy (group I) and radiotherapy (group II). For 68 patients, S-LD-1 was measured in a serum sample before or on the day of the orchiectomy. Twenty-seven patients (40%) had elevated S-LD-1; median 102 U/L (range 41-335). For the remaining 36 patients, S-LD-1 was measured in a serum sample after orchiectomy: 8 of these patients (22%) had elevated S-LD-1. S-LD-1 was normalized shortly after surgery in most patients with a preorchiectomy elevated S-LD-1. Fifteen of the 68 patients relapsed: 9 out of 27 with an elevated S-LD-1 and 6 out of 41 patients with normal S-LD-1 (p = 0.13, Fisher's exact test). In group I, those with a preoperatively elevated S-LD-1 had a lower 8-years' relapse-free survival than those with a normal S-LD-1 (40% ...
-
Serum Lactate Dehydrogenase Isoenzyme 1 as a prognostic predictor for metastatic testicular germ cell tumours.
British journal of cancer, 2000Co-Authors: Finn Edler Von Eyben, Ebbe Lindegaard Madsen, Frank J. Liu, Robert J. Amato, Herbert A. FritscheAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 as a prognostic predictor for metastatic testicular germ cell tumours
-
analytical quality specifications for serum Lactate Dehydrogenase Isoenzyme 1 based on clinical goals
Clinical Chemistry and Laboratory Medicine, 1999Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard MadsenAbstract:The aim of the study was to deduce analytical quality specifications for the determination of catalytic concentration of serum Lactate Dehydrogenase Isoenzyme 1 (S-LD-1) according to clinical goals (the clinical utility model). We defined clinical goals for false positive and false negative S-LD-1 measurements in the monitoring of patients with testicular germ cell tumors (TGCT), clinical stage I, on a surveillance only program. The absolute S-LD-1 catalytic concentrations were routinely corrected for contamination from preanalytical hemolysis. A reference group of 37 men had a near In-Gaussian distribution for the absolute S-LD-1 catalytic concentration. The geometric mean was 76 U/l and an S-LD-1 >128 U/l (99.72 percentile, the decision limit) indicated a high risk of a relapse of TGCT. We have previously shown that an S-LD-1 >160 U/l (treatment limit) was associated with a suboptimal outcome from the treatment of metastatic TGCT. The maximum allowable analytical positive bias was 5 U/l, and the maximum allowable analytical negative bias was -32 U/l. The maximum allowable analytical coefficient of variation, CV(A), was 11% (approximately 14 U/l) at a bias = -5 U/l. For S-LD-1 measurements not corrected for hemolysis, the decision limit was 145 U/l, the maximum allowable negative bias -19 U/l, and CV(A) 8%(approximately 12 U/l). A routine correction for hemolysis had a large impact on the analytical quality specifications.
Per Hyltoft Petersen - One of the best experts on this subject based on the ideXlab platform.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular and Ovarian Germ Cell Tumours
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, Mansoor Raza Mirza, B. HølundAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) is raised both in patients with ovarian germ cell tumours (OGCT) and with testicular germ cell tumours (TGCT). This overview combines results from the literature with the experience at a single oncological institution.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular Seminoma or Nonseminoma Stage I: Two Nationwide Danish Studies of Surveillance
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, G K Jacobsen, Lena Specht, Ebbe Lindegard Madsen, Mikael Rørth, H. Von Der MaaseAbstract:The use of surveillance in patients with stage I testicular germ cell tumours is increasing internationally. The aim of this study was to elucidate pathological and clinical aspects of serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration in this setting.
-
serum Lactate Dehydrogenase Isoenzyme 1 in patients with seminoma stage i followed with surveillance
Acta Oncologica, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, Lena Specht, Bent Pedersen, H. Von Der MaaseAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured in patients with testicular seminoma clinical stage I followed with surveillance after orchiectomy. The serum samples were obtained before orchiectomy in 110 patients (group A) and soon after orchiectomy in 55 patients (group B). In group A, 60 patients (55%) had elevated S-LD-1 and 10 patients (9%) had elevated serum human chorionic gonadotropin concentrations (S-hCG). In group B, median S-LD-1 was lower than that of group A and decreased with increasing time after orchiectomy (pae0.001, Jonckheere-Terpstra test, one-sided). After a median follow-up of 5.1 years, 23 patients (21%) in group A had relapses. The patients with elevated S-LD-1 and those with normal S-LD-1 had a similar relapse-free survival (pae0.79, log-rank test). Thus patients with seminoma stage I had elevated S-LD-1 more often than elevated S-hCG but an elevation in S-LD-1 did not predict a relapse during follow-up with surveillance. Further studies are required to elucidate the value of S-LD-1 in monitoring the surveillance of patients with seminoma stage I.
-
serum Lactate Dehydrogenase Isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage i
Acta Oncologica, 2001Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, H. Von Der Maase, Mikael RørthAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured at the time of orchiectomy in 104 patients with nonseminomatous testicular germ cell tumors (NSTGCT) clinical stage I who participated in a randomized study comparing surveillance after orchiectomy (group I) and radiotherapy (group II). For 68 patients, S-LD-1 was measured in a serum sample before or on the day of the orchiectomy. Twenty-seven patients (40%) had elevated S-LD-1; median 102 U/L (range 41-335). For the remaining 36 patients, S-LD-1 was measured in a serum sample after orchiectomy: 8 of these patients (22%) had elevated S-LD-1. S-LD-1 was normalized shortly after surgery in most patients with a preorchiectomy elevated S-LD-1. Fifteen of the 68 patients relapsed: 9 out of 27 with an elevated S-LD-1 and 6 out of 41 patients with normal S-LD-1 (p = 0.13, Fisher's exact test). In group I, those with a preoperatively elevated S-LD-1 had a lower 8-years' relapse-free survival than those with a normal S-LD-1 (40% ...
-
analytical quality specifications for serum Lactate Dehydrogenase Isoenzyme 1 based on clinical goals
Clinical Chemistry and Laboratory Medicine, 1999Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard MadsenAbstract:The aim of the study was to deduce analytical quality specifications for the determination of catalytic concentration of serum Lactate Dehydrogenase Isoenzyme 1 (S-LD-1) according to clinical goals (the clinical utility model). We defined clinical goals for false positive and false negative S-LD-1 measurements in the monitoring of patients with testicular germ cell tumors (TGCT), clinical stage I, on a surveillance only program. The absolute S-LD-1 catalytic concentrations were routinely corrected for contamination from preanalytical hemolysis. A reference group of 37 men had a near In-Gaussian distribution for the absolute S-LD-1 catalytic concentration. The geometric mean was 76 U/l and an S-LD-1 >128 U/l (99.72 percentile, the decision limit) indicated a high risk of a relapse of TGCT. We have previously shown that an S-LD-1 >160 U/l (treatment limit) was associated with a suboptimal outcome from the treatment of metastatic TGCT. The maximum allowable analytical positive bias was 5 U/l, and the maximum allowable analytical negative bias was -32 U/l. The maximum allowable analytical coefficient of variation, CV(A), was 11% (approximately 14 U/l) at a bias = -5 U/l. For S-LD-1 measurements not corrected for hemolysis, the decision limit was 145 U/l, the maximum allowable negative bias -19 U/l, and CV(A) 8%(approximately 12 U/l). A routine correction for hemolysis had a large impact on the analytical quality specifications.
H. Von Der Maase - One of the best experts on this subject based on the ideXlab platform.
-
Serum Lactate Dehydrogenase Isoenzyme 1 in Patients with Testicular Seminoma or Nonseminoma Stage I: Two Nationwide Danish Studies of Surveillance
Germ Cell Tumours V, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, G K Jacobsen, Lena Specht, Ebbe Lindegard Madsen, Mikael Rørth, H. Von Der MaaseAbstract:The use of surveillance in patients with stage I testicular germ cell tumours is increasing internationally. The aim of this study was to elucidate pathological and clinical aspects of serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration in this setting.
-
serum Lactate Dehydrogenase Isoenzyme 1 in patients with seminoma stage i followed with surveillance
Acta Oncologica, 2002Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, Lena Specht, Bent Pedersen, H. Von Der MaaseAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured in patients with testicular seminoma clinical stage I followed with surveillance after orchiectomy. The serum samples were obtained before orchiectomy in 110 patients (group A) and soon after orchiectomy in 55 patients (group B). In group A, 60 patients (55%) had elevated S-LD-1 and 10 patients (9%) had elevated serum human chorionic gonadotropin concentrations (S-hCG). In group B, median S-LD-1 was lower than that of group A and decreased with increasing time after orchiectomy (pae0.001, Jonckheere-Terpstra test, one-sided). After a median follow-up of 5.1 years, 23 patients (21%) in group A had relapses. The patients with elevated S-LD-1 and those with normal S-LD-1 had a similar relapse-free survival (pae0.79, log-rank test). Thus patients with seminoma stage I had elevated S-LD-1 more often than elevated S-hCG but an elevation in S-LD-1 did not predict a relapse during follow-up with surveillance. Further studies are required to elucidate the value of S-LD-1 in monitoring the surveillance of patients with seminoma stage I.
-
serum Lactate Dehydrogenase Isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage i
Acta Oncologica, 2001Co-Authors: Finn Edler Von Eyben, Ole Blaabjerg, Per Hyltoft Petersen, Ebbe Lindegaard Madsen, G K Jacobsen, H. Von Der Maase, Mikael RørthAbstract:Serum Lactate Dehydrogenase Isoenzyme 1 catalytic concentration (S-LD-1) was measured at the time of orchiectomy in 104 patients with nonseminomatous testicular germ cell tumors (NSTGCT) clinical stage I who participated in a randomized study comparing surveillance after orchiectomy (group I) and radiotherapy (group II). For 68 patients, S-LD-1 was measured in a serum sample before or on the day of the orchiectomy. Twenty-seven patients (40%) had elevated S-LD-1; median 102 U/L (range 41-335). For the remaining 36 patients, S-LD-1 was measured in a serum sample after orchiectomy: 8 of these patients (22%) had elevated S-LD-1. S-LD-1 was normalized shortly after surgery in most patients with a preorchiectomy elevated S-LD-1. Fifteen of the 68 patients relapsed: 9 out of 27 with an elevated S-LD-1 and 6 out of 41 patients with normal S-LD-1 (p = 0.13, Fisher's exact test). In group I, those with a preoperatively elevated S-LD-1 had a lower 8-years' relapse-free survival than those with a normal S-LD-1 (40% ...
